# US 2019/0315860 A1 · HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USE

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315860 A1
- Document ID: US20190315860A1
- Status: Published application
- Kind: A1
- Application number: 16/395,009
- Filed: 2019-04-25
- Published: 2019-10-17
- Earliest claimed: 2015-06-16
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Isidro HOTZEL; Teemu T. JUNTTILA; Ji LI; Justin SCHEER; Danielle DICARA; Diego ELLERMAN; Christoph SPIESS; Paul J. CARTER
- Web page: https://patentgrep.com/patent/US20190315860A1

## CPC

- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/30: from tumour cells
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/62: comprising only variable region components
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- G01N 2333/70535: Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.

## Claims

### Claim at position 1

1-335. (canceled)

### Claim 336

One or more isolated nucleic acids encoding an anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain that binds to FcRH5, the binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23.

### Claim 337 (depends on 336)

The one or more isolated nucleic acids of claim 336, wherein the binding domain comprises (a) a heavy chain variable (VH) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 104; (b) a light chain variable (VL) domain comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 105; or (c) a VH domain as in (a) and a VL domain as in (b).

### Claim 338 (depends on 336)

The one or more isolated nucleic acids of claim 336, wherein the anti-FcRH5 antibody further comprises the following heavy chain variable region framework regions (FRs):
(a) an FR-H1 comprising the amino acid sequence of SEQ ID NO: 52;
(b) an FR-H2 comprising the amino acid sequence of SEQ ID NO: 54;
(c) an FR-H3 comprising the amino acid sequence of SEQ ID NO: 46; and
(d) an FR-H4 comprising the amino acid sequence of SEQ ID NO: 47.

### Claim 339 (depends on 338)

The one or more isolated nucleic acids of claim 338, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 104.

### Claim 340 (depends on 336)

The one or more isolated nucleic acids of claim 336, wherein the anti-FcRH5 antibody further comprises the following light chain variable region FRs:
(a) an FR-L1 comprising the amino acid sequence of SEQ ID NO: 48;
(b) an FR-L2 comprising the amino acid sequence of SEQ ID NO: 57;
(c) an FR-L3 comprising the amino acid sequence of SEQ ID NO: 50; and
(d) an FR-L4 comprising the amino acid sequence of SEQ ID NO: 51.

### Claim 341 (depends on 340)

The one or more isolated nucleic acids of claim 340, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 105.

### Claim 342

One or more isolated nucleic acids encoding an anti-FcRH5 antibody, wherein the anti-FcRH5 antibody comprises a binding domain that binds to FcRH5, the binding domain comprising a binding domain comprising (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 104 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO: 105.

### Claim 343 (depends on 336)

The one or more isolated nucleic acids of claim 336, wherein the anti-FcRH5 antibody comprises a substitution mutation reducing the effector function of the anti-FcRH5 antibody or FcRH5-binding antibody fragment thereof.

### Claim 344 (depends on 343)

The one or more isolated nucleic acids of claim 343, wherein the substitution mutation is at amino acid residue N297, L234, L235, D265, and/or P329 (EU numbering).

### Claim 345 (depends on 344)

The one or more isolated nucleic acids of claim 344, wherein the substitution mutation is selected from the group consisting of N297G, N297A, L234A, L235A, D265A, and P329G.

### Claim 346 (depends on 345)

The one or more isolated nucleic acids of claim 345, wherein the substitution mutation is an N297G substitution mutation.

### Claim 347 (depends on 336)

The one or more isolated nucleic acids of claim 336, wherein the anti-FcRH5 antibody is a monoclonal, human, humanized, or chimeric antibody.

### Claim 348 (depends on 336)

The one or more isolated nucleic acids of claim 336, wherein the anti-FcRH5 antibody is an IgG antibody.

### Claim 349 (depends on 336)

The one or more isolated nucleic acids of claim 336, wherein the anti-FcRH5 antibody is an antibody fragment that binds FcRH5.

### Claim 350 (depends on 349)

The one or more isolated nucleic acids of claim 349, wherein the antibody fragment is selected from the group consisting of bis-Fab, Fab, Fab′-SH, Fv, scFv, and (Fab′)2 fragments.

### Claim 351 (depends on 336)

The one or more isolated nucleic acids of claim 336, wherein the anti-FcRH5 antibody is a full-length antibody.

### Claim 352 (depends on 336)

The one or more isolated nucleic acids of claim 336, wherein the anti-FcRH5 antibody is a multispecific antibody.

### Claim 353 (depends on 352)

The one or more isolated nucleic acids of claim 352, wherein the multispecific antibody is a bispecific antibody.

### Claim 354 (depends on 353)

The one or more isolated nucleic acids of claim 353, wherein the bispecific antibody comprises a second binding domain that binds cluster of differentiation 3 (CD3).

### Claim 355 (depends on 354)

The one or more isolated nucleic acids of claim 354, wherein the second binding domain binds to an epitope on CD3 comprising amino acid residue Glu6 of CD3.

### Claim 356 (depends on 355)

The one or more isolated nucleic acids of claim 355, wherein the second binding domain is capable of binding to a human CD3 polypeptide or a cyno CD3 polypeptide.

### Claim 357 (depends on 354)

The one or more isolated nucleic acids of claim 354, wherein the second binding domain comprises the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 117;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 120.

### Claim 358 (depends on 354)

The one or more isolated nucleic acids of claim 354, wherein the second binding domain comprises the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123.

### Claim 359

One or more isolated nucleic acids encoding an anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23; and
an anti-CD3 arm comprising a second binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123.

### Claim 360 (depends on 354)

The one or more isolated nucleic acids of claim 354, wherein the anti-FcRH5 antibody or FcRH5-binding antibody fragment thereof comprises one or more heavy chain constant domains, and wherein the one or more heavy chain constant domains are selected from a first CH2 domain (CH21), a first CH3 domain (CH31), a second CH2 domain (CH22), and a second CH3 domain (CH32).

### Claim 361 (depends on 360)

The one or more isolated nucleic acids of claim 360, wherein at least one of the one or more heavy chain constant domains is paired with another heavy chain constant domain.

### Claim 362 (depends on 361)

The one or more isolated nucleic acids of claim 361, wherein the CH31 and the CH32 each comprise a protuberance (P1) or a cavity (C1), and wherein the P1 or the C1 in the CH31 is positionable in the C1 or the P1, respectively, in the CH32.

### Claim 363 (depends on 362)

The one or more isolated nucleic acids of claim 362, wherein the CH31 and the CH32 meet at an interface between the P1 and the C1.

### Claim 364 (depends on 362, 363)

The one or more isolated nucleic acids of claim 362 or 363, wherein:
(a) the P1 comprises a T366W substitution mutation (EU numbering); and/or
(b) the C1 comprises T366S, L368A, and Y407V substitution mutations (EU numbering).

### Claim 365

One or more isolated nucleic acids encoding an anti-FcRH5 antibody that binds to FcRH5 and CD3, wherein the anti-FcRH5 antibody comprises an anti-FcRH5 arm comprising a first binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 8;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 9;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 12;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 16; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 23; and
an anti-CD3 arm comprising a second binding domain comprising the following six HVRs:
(a) an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 115;
(b) an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 116;
(c) an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 121;
(d) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 118;
(e) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 119; and
(f) an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 123; and
wherein the anti-FcRH5 arm and the anti-CD3 arm each comprise an N297G substitution mutation (EU numbering); and
wherein the anti-FcRH5 arm comprises a T366W substitution mutation (EU numbering) and the anti-CD3 arm comprises T366S, L368A, and Y407V substitution mutations (EU numbering).

### Claim 366 (depends on 336, 359)

One or more vectors comprising the one or more isolated nucleic acids of any one of claims 336, 359, and 365.

### Claim 367 (depends on 366)

One or more host cells comprising the one or more vectors of claim 366.

### Claim 368 (depends on 367)

The one or more host cells of claim 367, wherein the one or more host cells are one or more prokaryotic host cells.

### Claim 369 (depends on 368)

The one or more host cells of claim 368, wherein the one or more prokaryotic host cells are one or more E. coli host cells.

### Claim 370 (depends on 367)

The one or more host cells of claim 367, wherein the one or more host cells are one or more mammalian host cells.

### Claim 371 (depends on 370)

The one or more host cells of claim 370, wherein the one or more mammalian host cells are one or more Chinese hamster ovary (CHO) host cells.

### Claim 372 (depends on 367)

A method of producing an anti-FcRH5 antibody, the method comprising culturing the one or more host cells of claim 367 in a culture medium.

### Claim 373 (depends on 372)

The method of claim 372, wherein the method further comprises recovering the anti-FcRH5 antibody from the one or more host cells or the culture medium.
